Amgen Inc (AMGN)
A research Signal Score of unusual activity and the signals behind it. Not advice, not a prediction, not yet backtested.
Also measured against its sector ETF (XBI).
Our last 30 days of resolved calls came true 18% of the time.See the track record →
Figures reflect the most recent reported period. Margins, ROE and growth are percentages; Debt/Equity and Current ratio are ratios.
A generic 2:1 reward-to-risk example (about a 10% stop and 20% target). Illustrative and educational, not advice. Set your own levels for your risk tolerance.
- 12-month trend+39% over the past year+3
- 52-week positionIn the upper quarter of its 52-week range+18
- QualityStrong net margin (24%)+7
- VolumeNo intraday volume on the free data tier — this factor is disabled, not faked.+0
Score uses live volume/momentum/breakout signals today; insider buying, short interest, options flow and social velocity layer in as those sources come online. How it works →
🤖 The dominant catalyst is product/pipeline news, centered on the Phase III success for Amgen's acquired Sjögren's drug, with peer-valuation commentary and ETF flows as secondary noise. Continuation likelihood over the next few weeks is moderate (~40–50%), since single-trial readouts often fade without confirmatory data or regulatory milestones. Informational only — not financial advice.
- Spdr Dow Jones Industrial Avg ETF Trust (DIA) Buys $41.2 Million More GS on Nov. 11Yahoo · 2026-11-13
- Windward prices $175M IPO to advance China-licensed lung drugsYahoo · 2026-11-13
- Is Amgen Stock Priced Right Against Its Peers?Yahoo · 2026-11-12
- What Sent Revolution Medicines Stock Lower?Yahoo · 2026-11-12
- Amgen’s acquired Sjögren’s drug a Phase III hitYahoo · 2026-11-12
Any AI summary is an interpretation of public news, not advice or a price target.